The TRPV1 Pathway Wins the Nobel Prize and Why it Matters to AazeinTx
The common physiological mechanism between neuroinflammatory diseases that AazeinTx’s revolutionary immunomodulator affects is called the Transient Receptor Potential Vanilloid 1 (TRPV1). TRPV1 is an ion channel present on sensory neurons which is activated by heat, protons capsaicinm and a variety of endogenous lipids and inflammatory mediators.
Scientists behind the discovery of the TRPV1 pathway and its role as a molecular heat sensor in the body were announced as the winners of the Nobel Prize in Physiology or Medicine this year. Their seminal research explained for the first time how the human body feels and reacts heat sensations. Paralleling this purpose, however, was the realization this pathway plays in inflammation responses in the body, which would pave the way for important treatment developments for various inflammatory diseases involving the nervous system.
Further understandings have since been reached of TRPV1’s role in other physiological processes including its response to both neuroinflammation and local inflammation. AazeinTx’s lead scientist Dr. Richard Wilson took this understanding and uncovered the role TRPV1 plays in triggering and exacerbating acute asthma attacks. He launched extensive research into his discovery in his lab at the Cumming School of Medicine at the University of Calgary, publishing his findings in top medical journals including Nature Communications and Journal of Physiology.
It was through these efforts that he identified a suitable immunomodulator called NEO6860 that acted directly on the TRPV1 receptor, abating acute asthma in animal models.